Embudo, Ziefforah A.
HRN: 21-63-93 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/17/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/17/2022
08/24/2022
IV
53mg
Q24h
Soft Tissue Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes